Clinicohistopathological implications of MMP/VEGF expression in retinoblastoma: a combined meta-analysis and bioinformatics analysis

[1]  T. Corson,et al.  Retinoblastoma, the visible CNS tumor: A review , 2019, Journal of neuroscience research.

[2]  Jan Gorodkin,et al.  Cytoscape stringApp: Network analysis and visualization of proteomics data , 2018, bioRxiv.

[3]  C. Shields,et al.  Screening Children at Risk for Retinoblastoma: Consensus Report from the American Association of Ophthalmic Oncologists and Pathologists. , 2018, Ophthalmology.

[4]  Yi Huang,et al.  Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  J. Harbour.  Liquid Biopsy in Retinoblastoma. , 2017, JAMA ophthalmology.

[6]  J. Hicks,et al.  Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma , 2017, JAMA ophthalmology.

[7]  M. Diehn,et al.  Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[8]  S. Willems,et al.  The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis , 2017, Oncoimmunology.

[9]  C. Shields,et al.  HIGH-RISK INTRAOCULAR RETINOBLASTOMA: Comparison Between Asian Indians and Americans From Two Major Referral Centers , 2017, Retina.

[10]  Dianna A. Johnson,et al.  Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma , 2017, BMC Cancer.

[11]  A. Stacey,et al.  Focal laser treatment in addition to chemotherapy for retinoblastoma. , 2017, The Cochrane database of systematic reviews.

[12]  Pedro Fonseca,et al.  A novel community driven software for functional enrichment analysis of extracellular vesicles data , 2017, Journal of extracellular vesicles.

[13]  J. Collado-Vides,et al.  Effect of genomic distance on coexpression of coregulated genes in E. coli , 2017, PloS one.

[14]  B. Kristensen,et al.  Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas , 2017, PloS one.

[15]  S. Vacher,et al.  Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts. , 2016, Investigative ophthalmology & visual science.

[16]  H. Grossniklaus,et al.  Therapeutic Options for Retinoblastoma. , 2016, Cancer control : journal of the Moffitt Cancer Center.

[17]  Eleanor M. Pritchard,et al.  Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma. , 2016, Mini reviews in medicinal chemistry.

[18]  Yun Chen,et al.  Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.

[19]  L. Li,et al.  Correlation between matrix metalloproteinase-9 and vascular endothelial growth factor expression in lung adenocarcinoma. , 2015, Genetics and molecular research : GMR.

[20]  Gail M. Williams,et al.  Advances in the meta-analysis of heterogeneous clinical trials II: The quality effects model. , 2015, Contemporary clinical trials.

[21]  Ching-Seng Ang,et al.  FunRich: An open access standalone functional enrichment and interaction network analysis tool , 2015, Proteomics.

[22]  Yihai Cao,et al.  Invasiveness and metastasis of retinoblastoma in an orthotopic zebrafish tumor model , 2015, Scientific Reports.

[23]  B. Gao,et al.  The Effects of Modulation of MMP-2 and MMP-9 in Angiogenesis and Invasive Potential in Retinoblastoma , 2015 .

[24]  N. Youssef,et al.  Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies. , 2014, International journal of clinical and experimental pathology.

[25]  P. Carmeliet,et al.  The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses. , 2014, Cytokine & growth factor reviews.

[26]  T. Kivelä,et al.  Predicted Trends in the Incidence of Retinoblastoma in the Asia-Pacific Region , 2014, Asia-Pacific journal of ophthalmology.

[27]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases: changing roles in tumor progression and metastasis. , 2012, The American journal of pathology.

[28]  G. Opdenakker,et al.  VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. , 2012, Blood.

[29]  李海燕.  基质金属蛋白酶-1、-9和血管内皮生长因子在视网膜母细胞瘤组织中的表达 , 2012 .

[30]  B. Gallie,et al.  Retinoblastoma , 2012, The Lancet.

[31]  T. Lei,et al.  TNF-α-Induced VEGF and MMP-9 Expression Promotes Hemorrhagic Transformation in Pituitary Adenomas , 2011, International journal of molecular sciences.

[32]  Chang Sik Cho,et al.  Inhibitory Activity of Bevacizumab to Differentiation of Retinoblastoma Cells , 2011, PloS one.

[33]  Jia Xu,et al.  [Expression of matrix metalloproteinase-2,matrix metalloproteinase-9 and vascular endothdial growth factor in retinoblastoma and its clinical significance]. , 2010, Yan ke xue bao = Eye science.

[34]  Hua Song,et al.  [Expression and clinical implication of Matrix Metalloproteinase-1 and Vascular Endothelial Growth Factor in retinoblastoma]. , 2010, Yan ke xue bao = Eye science.

[35]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[36]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. , 2010, Seminars in cancer biology.

[37]  C. Shields,et al.  Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy , 2010, Current opinion in ophthalmology.

[38]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[39]  Chang Sik Cho,et al.  Differential roles of matrix metalloproteinase-9 and -2, depending on proliferation or differentiation of retinoblastoma cells. , 2010, Investigative ophthalmology & visual science.

[40]  M. Burnier,et al.  Expression of vascular endothelial growth factor in retinoblastoma. , 2010, Archives of ophthalmology.

[41]  宋华,et al.  Expression and clinical implication of hypoxia-inducible factor-1α and vascular endothelial growth factor in retinoblastoma , 2009 .

[42]  T. Kivelä.  The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death , 2009, British Journal of Ophthalmology.

[43]  A. Moll,et al.  Re: More about second cancers after retinoblastoma. , 2008, Journal of the National Cancer Institute.

[44]  Valérie Ferreira,et al.  VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. , 2008, European journal of cancer.

[45]  M. Tucker,et al.  Cancer screening practices of adult survivors of retinoblastoma at risk of second cancers , 2008, Cancer.

[46]  P. Luthert,et al.  Outcome of retinoblastoma in east Africa , 2008, Pediatric blood & cancer.

[47]  Suhail A R Doi,et al.  A Quality-Effects Model for Meta-Analysis , 2008, Epidemiology.

[48]  S. Plon,et al.  Retinoblastoma: review of current management. , 2007, The oncologist.

[49]  S. Krishnakumar,et al.  Expression of Matrix Metalloproteinases and Their Inhibitors in Retinoblastoma , 2007, Journal of pediatric hematology/oncology.

[50]  G. Beauchamp,et al.  The burden of age-related macular degeneration: a value-based analysis , 2006, Current opinion in ophthalmology.

[51]  A. LinnMurphree.  Intraocular retinoblastoma: the case for a new group classification. , 2005 .

[52]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[53]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[54]  Takanori Aoki,et al.  Matrix Metalloproteinases Cleave Connective Tissue Growth Factor and Reactivate Angiogenic Activity of Vascular Endothelial Growth Factor 165* , 2002, The Journal of Biological Chemistry.

[55]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[56]  P. Chévez-Barrios,et al.  Metastatic and nonmetastatic models of retinoblastoma. , 2000, The American journal of pathology.

[57]  Alan W. Stitt,et al.  Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra‐ocular tumours , 1998, The Journal of pathology.

[58]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[59]  S. Ya.  Expression of Livin,PTEN and MMP-9 in retinoblastoma and their correlation , 2014 .

[60]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[61]  A. Meadows,et al.  More about second cancers after retinoblastoma. , 2008, Journal of the National Cancer Institute.

[62]  A. Linn Murphree.  Intraocular retinoblastoma: the case for a new group classification. , 2005, Ophthalmology clinics of North America.

[63]  Du Jin-rong.  A Study of PCNA、VEGF Expression in Retinoblastoma , 2004 .

[64]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..